Literature DB >> 6859885

Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi.

R J Friedman, D S Rigel, A W Kopf, L Lieblich, R Lew, M N Harris, D F Roses, S L Gumport, A Ragaz, E Waldo, J Levine, M Levenstein, R Koenig, R S Bart, H Trau.   

Abstract

In a clinicohistopathologic study of 557 patients with primary cutaneous malignant melanoma, there were fewer metastases and/or deaths from melanoma when histologic evidence of a coexisting acquired melanocytic nevus was found. A total of 130 patients with melanocytic nevus and 427 cases of melanoma without histologic evidence of a nevus (denovo) were studied. Clinical follow-up evaluation for evidence of metastases and/or death was obtained. Only ten of the patients (7.7%) with nevus-associated melanoma had metastases and/or death v 78 (18.3%) with de novo melanoma. When stratified by lesion thickness, the logrank test for survival revealed a statistically significant difference between the two groups. An overall favorable outcome seen in patients with malignant melanomas associated with acquired melanocytic nevi was found, therefore, to be independent of lesion thickness as well as six other variables reported to be related to the biologic behavior of malignant melanoma. Thus, the presence of nevus cells in a specimen of malignant melanoma portends a better prognosis and may have important implications in the biology of this neoplasm.

Entities:  

Mesh:

Year:  1983        PMID: 6859885

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  8 in total

1.  Is There More Than One Road to Nevus-Associated Melanoma?

Authors:  Roberta Vezzoni; Claudio Conforti; Silvia Vichi; Roberta Giuffrida; Chiara Retrosi; Giovanni Magaton-Rizzi; Nicola Di Meo; Maria Antonietta Pizzichetta; Iris Zalaudek
Journal:  Dermatol Pract Concept       Date:  2020-04-03

2.  De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival.

Authors:  Rachel M Cymerman; Yongzhao Shao; Kun Wang; Yilong Zhang; Era C Murzaku; Lauren A Penn; Iman Osman; David Polsky
Journal:  J Natl Cancer Inst       Date:  2016-05-27       Impact factor: 13.506

3.  RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy.

Authors:  Ichiro Yajima; Mayuko Y Kumasaka; Nguyen Dinh Thang; Yuji Goto; Kozue Takeda; Osamu Yamanoshita; Machiko Iida; Nobutaka Ohgami; Haruka Tamura; Yoshiyuki Kawamoto; Masashi Kato
Journal:  Dermatol Res Pract       Date:  2011-10-12

4.  Clinicopathological, Genetic and Survival Advantages of Naevus-associated Melanomas: A Cohort Study.

Authors:  Xavier Bosch-Amate; Sebastian Podlipnik; Constanza Riquelme-Mc Loughlin; Cristina Carrera; Alicia Barreiro-Capurro; Adriana García-Herrera; Llucia Alós; Josep Malvehy; Susana Puig
Journal:  Acta Derm Venereol       Date:  2021-03-31       Impact factor: 3.875

5.  A clinicopathological analysis of 153 acral melanomas and the relevance of mechanical stress.

Authors:  Yi-Shuan Sheen; Yi-Hua Liao; Ming-Hsien Lin; Jau-Shiuh Chen; Jau-Yu Liau; Yu-Ju Tseng; Chih-Hung Lee; Yih-Leong Chang; Chia-Yu Chu
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

6.  Clinicopathological features and prognosis of patients with de novo versus nevus-associated melanoma in Taiwan.

Authors:  Yi-Shuan Sheen; Yi-Hua Liao; Ming-Hsien Lin; Jau-Shiuh Chen; Jau-Yu Liau; Cher-Wei Liang; Yih-Leong Chang; Chia-Yu Chu
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

7.  Nevus-Associated versus de novo Melanoma: Do They Have Different Characteristics and Prognoses?

Authors:  Nilay Duman; Gül Erkin; Özay Gököz; Sevilay Karahan; Aycan Uğur Kayıkçıoğlu; İsmail Çelik
Journal:  Dermatopathology (Basel)       Date:  2015-04-01

8.  Risk factors of recurrence and distant metastasis in primary cutaneous melanoma in Taiwan.

Authors:  Tung-Lin Lee; Yi-Hua Liao; Jau-Yu Liau; Yi-Shuan Sheen
Journal:  Sci Rep       Date:  2021-10-25       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.